Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials